Mutations in IDH are seen in an estimated 14–20% of AML patients, with IDH1 mutations occurring in 3–20% of cases and IDH2 mutations in 9–20% of cases [6–9]. This evidence concerns the gene IDH2 and acute myeloid leukemia.